Healthcare
Median Technologies: H2 2026 Financial Communication Calendar
SOPHIA ANTIPOLIS, France, September 10, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today its H2 2026 financial communication calendar.
About this update from Median Technologies
SOPHIA ANTIPOLIS, France, September 10, 2026 --( BUSINESS WIRE )--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") , developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today its H2 2026 financial communication calendar. The Company will participate in upcoming investor events: European MidCap Event 2026 - September 30 – October 1st, 2026 - Paris, France Investor Access Conference 2026 - October 6-7, 2026 - Paris, France Portzamparc Biotech and Healthcare Sector Investor Seminar - October 14-15, 2026 (digital) Please get in touch through the respective event booking systems, if you would like to request a meeting with Median management at these events. Events are for institutional investors only. About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20260910527817/en/ Contacts MEDIAN TECHNOLOGIES Emmanuelle Leygues VP, Corporate Marketing & Financial Communications +33 6 10 93 58 88 [email protected] Investors - SEITOSEI ACTIFIN Ghislaine Gasparetto +33 6 85 36 76 81 [email protected] Media – MAARC Bruno Arabian +33 6 87 88 47 26 [email protected]
View stock analysis, news, and events for Median Technologies